By Patrick Wingrove and Bhanvi Satija (Reuters) - Johnson & Johnson (NYSE:), contemporary off a $14.6 billion deal to purchase neurological drugmaker Intra-Mobile, reported fourth-quarter gross sales and revenue above Wall Road...
This text was written byObserveBrendan, a Pennsylvanian by delivery:-Accomplished a Ph.D. at Stanford College within the discipline of natural synthesis (2009). -Labored for a serious pharmaceutical firm (Merck, 2009-2013).-Labored in biotech together with...
This textual content was written by
Terry Chrisomalis is a personal investor throughout the Biotech sector with years of experience utilizing his Utilized Science background to generate long term price from Healthcare.
He’s the...
By Ludwig Burger (Reuters) - Sanofi (NASDAQ:)'s most superior a number of sclerosis (MS) drug candidate has missed the principle aim of two late-stage trials to deal with relapsing types...
By Maggie FickLONDON (Reuters) -Novo Nordisk on Wednesday trimmed its full-year income outlook after reporting weaker-than-expected quarterly product sales of its widespread weight-loss drug Wegovy, stirring worries amongst patrons about stiffening rivals from...
Shares of Invivyd (NASDAQ:IVVD) closed 42% increased Friday after the biotech firm introduced it had obtained FDA emergency use authorization, or EUA, for its COVID-19 prophylactic drug Pemgarda and launched Part...
